Clario to Acquire WCG's eCOA Business

Clario, a leading provider of endpoint data solutions for the clinical trial industry, has announced a definitive agreement to acquire WCG's electronic clinical outcomes assessments (eCOA) business. This strategic acquisition will boost Clario's capabilities, particularly in neuroscience, by adding WCG's scientific and operational expertise in neurology, psychiatry, neuropathic pain, and rare diseases. Clario's CEO, Chris Fikry, stated that the acquisition aligns with the company’s mission to transform lives through actionable evidence. From WCG’s perspective, CEO Sam Srivastava explained that the deal will allow the firm to focus on other core capabilities such as accelerating trials, leveraging its AI-enabled data solutions. Both companies will continue operations independently until the acquisition finalizes, subject to regulatory approvals.